Dimensional Fund Advisors LP Buys 135,007 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Dimensional Fund Advisors LP grew its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 10.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,488,667 shares of the medical instruments supplier’s stock after acquiring an additional 135,007 shares during the period. Dimensional Fund Advisors LP’s holdings in AngioDynamics were worth $13,636,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ANGO. SBI Securities Co. Ltd. bought a new position in AngioDynamics during the fourth quarter valued at $28,000. JPMorgan Chase & Co. grew its stake in shares of AngioDynamics by 28.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock worth $4,304,000 after acquiring an additional 123,271 shares during the period. Barclays PLC increased its holdings in AngioDynamics by 81.0% in the 3rd quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock worth $651,000 after acquiring an additional 37,394 shares during the last quarter. Bank of New York Mellon Corp raised its stake in AngioDynamics by 3.2% in the 4th quarter. Bank of New York Mellon Corp now owns 122,676 shares of the medical instruments supplier’s stock valued at $1,124,000 after acquiring an additional 3,815 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in AngioDynamics during the fourth quarter valued at about $879,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Up 5.7 %

Shares of NASDAQ ANGO opened at $9.27 on Friday. The business has a 50-day simple moving average of $9.43 and a two-hundred day simple moving average of $9.29. AngioDynamics, Inc. has a 52 week low of $5.47 and a 52 week high of $13.50. The company has a market cap of $376.31 million, a P/E ratio of -1.65 and a beta of 0.58.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.00 million during the quarter, compared to analysts’ expectations of $70.30 million. The business’s quarterly revenue was down 4.3% on a year-over-year basis. Equities research analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target (up from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.